Once we settle on what that dose to use — the doses to use moving forward in combination in expansion studies we expect that to occur by the end of the year. So, again, could it be the first half of the year possible. But right now, let me bring you up to date once we have picked that those doses and started those expansions, I’ll be able to give you a little bit more definition when that will happen.
Peter Lawson: Got you. Thank you. And then [Indiscernible] and I know there’s an update this year. Kind of what kind of update will that be? Will we see data? Is it kind of a go no-go decision? And will the data involve the lung cancer data?
Scott Koenig: So, as you know, and we discussed this before, ImmunoGen is conducting a clinical studies. The following through on the patients with lung cancer to identify an appropriate, they’re making decisions about go forward. We have not discussed with them the specifics about what would be discussed and presented, we should be doing that soon. So, again, updates later this year, the nature of what will be contained. I don’t have an answer to you at this time.
Peter Lawson: Okay. Thanks so much Scott.
Operator: Thank you. Our next question comes from Charles Zhu with Guggenheim. Your line is open.
Unidentified Analyst : Hi guys. This is Rosy [ph] on for Charles Zhu. Thanks for taking our question. So, first question is with regard to the change in landscape and mCRPC. How are you changing or selling expectations with regards to the valid positioning of vobra duo and lorigerlimab next to something like PLUVICTO?
Scott Koenig: So, if I understand your question, how are we anticipating the use of these drugs in face of where PLUVICTO is at this point and in the future. Is that correct?
Unidentified Analyst: Yes.
Scott Koenig: Okay. So, clearly, PLUVICTO is — has changed the landscape treatment. It is being used currently right now in major medical centers that have PET scanning capabilities for PSMA. There has been, as you know, some limitation in its distribution in terms of supply, which is being addressed by Novartis. So, there will be increased use with time I think at this point, we have to wait to see the data on the results of PLUVICTO in earlier lines of therapy. So right now, it’s more in a later line of therapy. When we have completed our study results, we will evaluate where the appropriate line of therapy will be in which populations. But right now, it’s just too early. Also, mechanistically, we’re talking about completely different mechanisms and also the toxicity profiles are quite different.
And so I think that this is an opportunity where different mechanisms of action give greater number of choices for treating physicians and their patients. So, I think it’s a good story for patients that new modalities will be available very soon.
Unidentified Analyst: Thank you. And if I can ask the second real quick on this one is regarding the vobra duo combo. Are there specific histologies that you potentially want to focus on for the dose expansion?
Scott Koenig: Well, as we pointed out in today’s call and previously, we are looking at six different solid tumor types right now. we have not selected which ones to do yet for the expansion. Certainly, prostate cancer will be one of them which additional others we will select, we have yet to make that decision. And we’ll again, in the near-term, we’ll be able to provide that information.
Operator: Thank you. Our next question comes from Etzer Darout with BMO Capital Markets. Your line is open.
